SPIKE FLOW endocardial pacing lead safety and performance study
Official title: A Prospective Multi-center Single Arm Study Evaluating the Safety and Performance of the SPIKE FLOW Endocardial Lead
Run by FIAB SpA · NCT07820072 · Data updated 2026-11-12
This study tests whether the SPIKE FLOW temporary endocardial pacing lead is safe and effective in adults needing temporary pacing during heart-related conditions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 131 (estimated) |
| Sponsor | FIAB SpA Industry-sponsored |
| Locations | 3 sites (Acquaviva delle Fonti, Bari and 2 other locations) |
| Status | Recruiting |
| Started | August 7, 2026 |
| Main results expected | July 2027 |
| Study ends | August 2027 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT07820072 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older undergoing a procedure requiring temporary cardiac pacing or evaluated for transient vs permanent bradycardia, who consent to participate.
✕Probably not a fit
Patients already implanted with permanent pacing or defibrillator, or those in cardiogenic shock or with certain exclusion conditions, may not benefit from this device in this setting.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, non-randomized, single-arm study evaluates the safety and performance of the SPIKE FLOW temporary endocardial pacing leads across multiple centers in Italy. Primary endpoints look at safety as freedom from Serious Adverse Events and pacing performance via mean capture threshold. Secondary endpoints include freedom from Adverse Events, impedance, and sensed R-wave amplitude. Approximately 131 adults undergoing procedures requiring temporary pacing will be enrolled over about one year with follow-up visits around lead insertion and removal.
Why it matters
Potential benefit: If successful, the SPIKE FLOW leads could provide reliable temporary cardiac pacing with predictable performance during short-term clinical needs.
How similar studies have gone: Prior studies of temporary endocardial leads have demonstrated feasibility and safety in similar contexts, but this specific SPIKE FLOW device is being evaluated in a non-randomized, single-arm design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject undergoing a surgical or an interventional procedure, requiring temporary cardiac pacing per investigator's medical judgment or subjects with bradycardia who are under evaluation to determine if the cause is transient or permanent; * Subject is at least 18 years of age; * Subject provides written informed consent to the study. Exclusion Criteria: * Subject has a co-existing temporary pacing or an implanted active permanent pacemaker or a cardiac defibrillator; * Subject in cardiogenic shock; * Subject is currently in atrial fibrillation; * Subject is pregnant or breastfeeding; * Subject had a stroke within 6 months prior to enrollment; * Subject has renal insufficiency with creatinine \>2 mg/dl; * Subject with known bleeding diathesis; * Subject with a history of deep vein thrombosis or pulmonary embolism within 6 months; * Subject with known tricuspid valve disease that may impede catheter advancement to and withdrawal from the right ventricle; * Subject with known intracardiac thrombus or vegetation on echocardiography; * Subject with significant neck abnormalities such that placement of a right and/or left internal jugular vein line would be difficult; * Subject has an active systemic infection or local infection at or around the insertion site; * Subject is involved in another clinical study that could influence the safety or outcome measures of this study.
Where it's running
-
Ospedale del Cuore 'G. Pasquinucci' Fondazione Toscana 'Gabriele Monasterio'
Massa, Massa-Carrara, Italy Recruiting -
Azienda Ospedaliero Universitaria Pisana
Pisa, Pisa, Italy Recruiting -
Ospedale Generale Regionale "F. Miulli"
Acquaviva delle Fonti, Bari, Italy Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LivIQ leadless pacemaker system for ventricular pacing
This trial will test the LivIQ leadless pacemaker in adults who need ventricular pacing (VVI or VDD) to see if it is safe and maintains appropriate heart rhythm and AV timing.
-
Can 1-Hz rTMS help with heart rhythm and inflammation after a heart attack?
This trial tests whether daily 1-Hz repetitive transcranial magnetic stimulation can improve heart rate variability and reduce inflammation in people who have had an acute myocardial infarction, compared with a sham procedure.
-
Trends and risk factors for adverse events after primary PCI in AMI patients over 20 years
This study looks at real-world AMI patients who had a primary PCI to see how often serious events happen during a 2-year follow-up and what factors predict them.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Factors Linked to Slow Heart Rate After Pulsed Field Ablation for Atrial Fibrillation
This study looks for factors that might cause bradycardia during the hospital stay after AF ablation using pulsed field technology.
-
Transjugular implantation of a leadless pacemaker (Aveir VR) for ventricular pacing
This study tests whether placing an Aveir VR leadless pacemaker through the neck vein can safely provide ventricular pacing in adults with bradycardia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.